



Open Government Impact Statement

80th Oregon Legislative Assembly
2019 Regular Session

Measure: SB 910 - A

Only impacts on Original or Engrossed
Versions are Considered Official

Prepared by: Cameron D. Miles
Date: 4/17/2019

SUMMARY

Requires retail or hospital pharmacy to provide written notice in conspicuous manner of availability of naloxone at pharmacy. Requires pharmacist, upon being presented with prescription for opiate or opioid of specified strength, to offer to prescribe and provide naloxone kit.

Removes requirement for written approval by parole or probation officer for administration of synthetic opiate as treatment for opiate addiction if requirements of statute are met.

Narrows Allows county or local public health authority to waive siting restrictions on methadone clinics to *clinics providing outpatient treatment* extent necessary to remove unreasonable barriers to patients' access to treatment.

Requires monitoring of naloxone equivalents by prescription drug monitoring program. Permits Oregon Health Authority to identify by rule other drugs that are subject to monitoring under program. Removes requirement for pharmacy to report name, address, phone number, date of birth and sex of patient for whom naloxone was prescribed.

Allows pharmacy, health care professional or pharmacist to distribute multiple naloxone kits to social service agencies or other persons who work with individuals who have experienced opiate overdose and allows subsequent distribution to individual likely to experience opiate overdose or family member of individual.

Takes effect on 91st day following adjournment sine die.

NOTICE OF NO OPEN GOVERNMENT IMPACT